Alta Charo served on a National Academies committee whose recommendations for reform of the oversight system for human gene therapy trials were accepted in full by the director of the National Institutes of Health. The new system streamlines regulation while still protecting patients and providing a platform for public debate about using genetic modification to treat diseases.

Submitted by Law School News on May 22, 2014

This article appears in the categories: Activities & Scholarship